COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer.

I P M Tomlinson, M Dunlop, H Campbell, B Zanke, S Gallinger, T Hudson, T Koessler, P D Pharoah, I Niittymäki, I Niittymäkix, S Tuupanen, S Tuupanenx, L A Aaltonen, K Hemminki, A Lindblom, A Försti, O Sieber, L Lipton, T van Wezel, H Morreau, J T Wijnen, P Devilee, K Matsuda, Y Nakamura, S Castellví-Bel, C Ruiz-Ponte, A Castells, A Carracedo, J W C Ho, P Sham, R M W Hofstra, P Vodicka, H Brenner, J Hampe, C Schafmayer, J Tepel, S Schreiber, H Völzke, M M Lerch, C A Schmidt, S Buch, V Moreno, C M Villanueva, P Peterlongo, P Radice, M M Echeverry, A Velez, L Carvajal-Carmona, R Scott, S Penegar, P Broderick, A Tenesa, R S Houlston
Year of publication:
Journal title abbreviated:
Journal title long:
The British journal of cancer : the clinical and scientific journal of The Cancer Research Campaign : BJC
Impact factor:
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.